Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & Korsinsky

Core Viewpoint - A class action securities lawsuit has been filed against Novo Nordisk A/S, alleging securities fraud that negatively impacted investors between May 7, 2025, and July 28, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Novo Nordisk made misleading statements about its growth potential, particularly regarding the compounded GLP-1 market and the likelihood of patients switching to its branded products [2]. - On July 29, 2025, Novo Nordisk lowered its sales and profit outlook, citing reduced growth expectations for its products Wegovy and Ozempic due to competition and market conditions [2]. - Following the announcement, Novo's stock price dropped from $69.00 to $53.94 per share, a decline of approximately 21.83% in one day [2]. Group 2: Investor Information - Investors who suffered losses during the specified period have until September 30, 2025, to request to be appointed as lead plaintiff in the lawsuit [3]. - Class members may be eligible for compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].